Mark Cooper, PhD - LDN, Neuroinflammation, and Movement Disorders (2018 Conference) (LDN, low dose naltrexone)
Dr Mark Cooper co-wrote a paper with Pradeep Chopra entitled “Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN)”, this paper can be found here https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661907/
In this presentation Mark Cooper discusses two clinical cases as described in the journal above about a 48 year old man who had the autoimmune disorder Complex Regional Pain Syndrome (CRPS) and a 12 year old female patient with Ehlers-Danlos Syndrome (EDS) with multiple complications, she first developed CRPS in her lower right extremity in 2008 and developed dystonic muscle spasms in the upper extremities a year later. Both of these patients were treated with Low Dose Naltrexone (LDN) and both showed spectacular outcomes, totally unexpected, given the severity of the symptoms.
Dr Mark Cooper then goes on to explain several areas: one, the loss of the pain gate, the sensory gates to the spinal cord. The second, how inflammation can spread into the brain through axonal tracks, spreading into subcortical regions, like the thalamus and how these types of behaviours are augmented in neuro autoimmune disorders where autoantibodies are in play. He explains a set of interlocking pathologies that involve injured nerves and activated Glia, microglia and reactive astrocytes.
He concludes that LDN offers a therapeutic option to arrest the assembly of a pathological state using these cellular, molecular elements. And in some cases, as we've seen, Low Dose Naltrexone can actually lead to a remission of these symptoms.
Thank you for listening to this presentation. All past conference presentations can be found on our website, https://ldnresearchtrust.org/